Lotus Pharmaceutical Co., Ltd. (TPE: 1795)
Taiwan
· Delayed Price · Currency is TWD 269.00
+4.50 (1.70%)
Jan 6, 2025, 1:30 PM CST
Lotus Pharmaceutical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 17,594 | 16,958 | 14,633 | 12,649 | 10,729 | 9,611 | Upgrade
|
| Revenue Growth (YoY) | 5.29% | 15.89% | 15.68% | 17.90% | 11.63% | 49.50% | Upgrade
|
| Cost of Revenue | 7,673 | 7,574 | 6,827 | 7,009 | 6,132 | 5,189 | Upgrade
|
| Gross Profit | 9,921 | 9,384 | 7,806 | 5,640 | 4,597 | 4,422 | Upgrade
|
| Selling, General & Admin | 4,102 | 3,764 | 3,141 | 2,703 | 2,473 | 2,544 | Upgrade
|
| Research & Development | 503.33 | 541.46 | 419.01 | 373.84 | 384.14 | 465.48 | Upgrade
|
| Operating Expenses | 4,597 | 4,302 | 3,557 | 3,112 | 2,856 | 3,010 | Upgrade
|
| Operating Income | 5,324 | 5,082 | 4,249 | 2,529 | 1,740 | 1,412 | Upgrade
|
| Interest Expense | -576.04 | -533.69 | -356.22 | -266.69 | -304.45 | -350.36 | Upgrade
|
| Interest & Investment Income | 86.24 | 31.55 | 3.51 | 5.34 | 3.76 | 7.86 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 3.78 | -0.68 | Upgrade
|
| Currency Exchange Gain (Loss) | 31.76 | 91.67 | -81.22 | -119.23 | 40.45 | 99.23 | Upgrade
|
| Other Non Operating Income (Expenses) | 48.1 | 23.94 | -10.31 | 1.78 | -9.4 | 30.07 | Upgrade
|
| EBT Excluding Unusual Items | 4,914 | 4,696 | 3,805 | 2,150 | 1,474 | 1,198 | Upgrade
|
| Gain (Loss) on Sale of Investments | 695.43 | 715.05 | 286.81 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -25.39 | -24.75 | 2.52 | -3.2 | -4.68 | -9.45 | Upgrade
|
| Asset Writedown | -179.37 | -179.37 | -138.26 | -233.18 | -127.68 | -211.25 | Upgrade
|
| Other Unusual Items | -31.14 | -103.79 | -16 | -43.42 | -40.31 | -88.96 | Upgrade
|
| Pretax Income | 5,373 | 5,103 | 3,940 | 1,870 | 1,302 | 888.06 | Upgrade
|
| Income Tax Expense | 1,041 | 997.3 | 919.46 | 466.65 | 274.58 | 209.78 | Upgrade
|
| Earnings From Continuing Operations | 4,333 | 4,106 | 3,021 | 1,403 | 1,027 | 678.28 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | -0.42 | -15.48 | Upgrade
|
| Net Income | 4,333 | 4,106 | 3,021 | 1,403 | 1,027 | 662.81 | Upgrade
|
| Net Income to Common | 4,333 | 4,106 | 3,021 | 1,403 | 1,027 | 662.81 | Upgrade
|
| Net Income Growth | 11.87% | 35.91% | 115.25% | 36.67% | 54.92% | 566.30% | Upgrade
|
| Shares Outstanding (Basic) | 262 | 261 | 261 | 255 | 243 | 242 | Upgrade
|
| Shares Outstanding (Diluted) | 263 | 262 | 262 | 257 | 243 | 242 | Upgrade
|
| Shares Change (YoY) | 0.37% | 0.13% | 1.95% | 5.43% | 0.65% | 1.55% | Upgrade
|
| EPS (Basic) | 16.56 | 15.72 | 11.59 | 5.50 | 4.22 | 2.74 | Upgrade
|
| EPS (Diluted) | 16.48 | 15.67 | 11.54 | 5.47 | 4.22 | 2.74 | Upgrade
|
| EPS Growth | 11.43% | 35.79% | 110.97% | 29.62% | 54.02% | 556.11% | Upgrade
|
| Free Cash Flow | 4,316 | 1,204 | 3,142 | -453.07 | 1,535 | 86.54 | Upgrade
|
| Free Cash Flow Per Share | 16.42 | 4.59 | 12.01 | -1.77 | 6.30 | 0.36 | Upgrade
|
| Dividend Per Share | 4.647 | 4.647 | 3.460 | 1.930 | 0.350 | - | Upgrade
|
| Dividend Growth | 34.32% | 34.32% | 79.27% | 451.43% | - | - | Upgrade
|
| Gross Margin | 56.39% | 55.34% | 53.35% | 44.59% | 42.84% | 46.01% | Upgrade
|
| Operating Margin | 30.26% | 29.97% | 29.04% | 19.99% | 16.22% | 14.69% | Upgrade
|
| Profit Margin | 24.63% | 24.21% | 20.64% | 11.09% | 9.57% | 6.90% | Upgrade
|
| Free Cash Flow Margin | 24.53% | 7.10% | 21.47% | -3.58% | 14.31% | 0.90% | Upgrade
|
| EBITDA | 6,466 | 6,171 | 5,094 | 3,204 | 2,365 | 1,829 | Upgrade
|
| EBITDA Margin | 36.75% | 36.39% | 34.81% | 25.33% | 22.04% | 19.03% | Upgrade
|
| D&A For EBITDA | 1,142 | 1,088 | 844.44 | 675.77 | 624.19 | 417 | Upgrade
|
| EBIT | 5,324 | 5,082 | 4,249 | 2,529 | 1,740 | 1,412 | Upgrade
|
| EBIT Margin | 30.26% | 29.97% | 29.04% | 19.99% | 16.22% | 14.69% | Upgrade
|
| Effective Tax Rate | 19.36% | 19.54% | 23.34% | 24.95% | 21.09% | 23.62% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.